Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
Dyne Therapeutics (Nasdaq: DYN) closed an upsized underwritten public offering on Dec 11, 2025, selling 21,827,549 shares of common stock at a public offering price of $18.44 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Dyne Therapeutics (Nasdaq: DYN) closed an upsized underwritten public offering on Dec 11, 2025, selling 21,827,549 shares of common stock at a public offering price of $18.44 per share.
The total gross proceeds to Dyne were approximately $402.5 million before underwriting discounts, commissions and offering expenses. The offering included 2,847,071 shares issued upon full exercise of the underwriters' option to purchase additional shares. All shares were sold by Dyne under a shelf registration on Form S-3 that became effective March 5, 2024.
Positive
- Gross proceeds of approximately $402.5 million
- Underwriters exercised option for 2,847,071 additional shares
Negative
- Issued 21,827,549 new shares, diluting existing shareholders
- Net proceeds reduced by underwriting discounts, commissions and offering expenses
Details
News Market Reaction – DYN
On Dec 12, the first trading day after this news, DYN closed 0.77% below the previous close.
Data tracked by StockTitan Argus for the Dec 12 session.
Key Figures
- Shares offered
- 21,827,549 shares
- Total common shares in this underwritten public offering
- Underwriters’ option shares
- 2,847,071 shares
- Additional shares from full exercise of underwriters’ option
- Offering price
- $18.44 per share
- Public offering price for common stock
- Gross proceeds
- $402.5 million
- Gross proceeds before underwriting discounts and expenses
Historical Context
-
Priced upsized equity offering at $18.44 with significant gross proceeds.
-
Announced proposed $300M equity raise plus $45M underwriter option.
-
Reported positive Phase 1/2 DELIVER results with strong dystrophin increases.
-
Q3 results with substantial net loss offset by strong cash position and updates.
-
Planned presentations at multiple healthcare investor conferences.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
underwritten public offering financial
gross proceeds financial
prospectus supplement regulatory
book-running managers financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the closing of its previously announced upsized underwritten public offering of 21,827,549 shares of its common stock at a public offering price of
Morgan Stanley, Jefferies, Stifel and Guggenheim Securities acted as joint book-running managers for the offering.
The offering was made pursuant to a shelf registration statement on Form S-3 that was previously filed with the Securities and Exchange Commission (“SEC”) on March 5, 2024 and became automatically effective upon filing. The offering was made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A final prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and may be obtained for free by visiting the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus may also be obtained by contacting: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at prospectus@morganstanley.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com.
This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Dyne Therapeutics
Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities.
Contacts:
Investors
Mia Tobias
ir@dyne-tx.com
781-317-0353
Media
Stacy Nartker
snartker@dyne-tx.com
781-317-1938
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.